{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-23-000219","form_type":"8-K","ticker":"AXIM","cik":"0001514946","company_name":"AXIM BIOTECHNOLOGIES, INC.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.343443+00:00","generated_at":"2026-06-20T07:09:57.224959+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AXIM cures defaults on $5.3M in debt, cuts conversion prices, gives CEO $250K note for back pay","bullets":["TL-66 waives $216,572 interest on $934,478 secured notes; conversion price cut to $0.04 from $0.2201.","MMI waives $261,537 interest on $4M note; conversion price cut to $0.075 from $0.25.","CEO forgives $50K of $512.5K back salary; gets $250K note at $0.01; $212.5K deferred to July 1, 2023.","CEO salary cut by $55,000 for H1 2023 to preserve working capital.","Additional interest waivers on TL-66 ($11,191) and Sapphire ($17,116) notes."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-23-000219","json":"https://secwatch.observer/filing/0001096906-23-000219.json","markdown":"https://secwatch.observer/filing/0001096906-23-000219.md","text":"https://secwatch.observer/filing/0001096906-23-000219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623000219/0001096906-23-000219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623000219/axim-20230123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:09:57.224959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cf2ba027108f451647170f997c06ca1d1e7fe29","claim":"AXIM BIOTECHNOLOGIES, INC. incurred convertible notes of $250,000 with John W. Huemoeller II at 4% per annum maturing January 1, 2033.","evidence_excerpt":"John W. Huemoeller II Settlement Agreement On January 23, 2023, the Company entered into a “Settlement Agreement” with its Chief Executive Officer, John W.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623000219/0001096906-23-000219-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$250,000"},{"label":"Counterparty","value":"John W. Huemoeller II"},{"label":"Rate","value":"4% per annum"},{"label":"Maturity","value":"January 1, 2033"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"1b8f06299faa666865fe017a2b959833c3dedf45","claim":"AXIM BIOTECHNOLOGIES, INC. entered into Convertible Notes Modification and Default Waiver Agreement with TL-66 LLC valued at Aggregate face value of Secured Notes: $934,478; interest waived: $216,572; conversion price reduced (effective 2023-01-23).","evidence_excerpt":"On January 23, 2023, AXIM Biotechnologies, Inc. (the “Company”) and TL-66 LLC entered into a Convertible Notes Modification and Default Waiver Agreement (“Waiver Agreement”) in order to modify and cure defaults on various notes issued by the Company and its subsidiaries to TL-66 as summarized below.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623000219/0001096906-23-000219-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"TL-66 LLC"},{"label":"Value","value":"Aggregate face value of Secured Notes: $934,478; interest waived: $216,572; conversion price reduced"},{"label":"Effective","value":"2023-01-23"}],"fact_type":"material_agreement"},{"claim_id":"1bf3293e4fcd059b624288734b654bcc10a389f8","claim":"AXIM BIOTECHNOLOGIES, INC. entered into Convertible Note Modification and Default Waiver Agreement with Medical Marijuana, Inc valued at Face value $4,000,000; interest waived: $261,536.96; conversion price reduced to $0.075; interest ra (effective 2023-01-23).","evidence_excerpt":"On January 23, 2023, the Company and Medical Marijuana, Inc (\"MMI\") entered into a Convertible Note Modification and Default Waiver Agreement (“MMI Modification Agreement”) in order to modify and cure the default of a convertible note, as amended, face value $4 million, issued by the Company to MMI (the \"MMI Convertible Note\") as set forth below.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623000219/0001096906-23-000219-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Medical Marijuana, Inc"},{"label":"Value","value":"Face value $4,000,000; interest waived: $261,536.96; conversion price reduced to $0.075; interest ra"},{"label":"Effective","value":"2023-01-23"}],"fact_type":"material_agreement"},{"claim_id":"687444bca3845aab82740d9557876f6ba2b1c968","claim":"AXIM BIOTECHNOLOGIES, INC. entered into Settlement Agreement with John W. Huemoeller II valued at Accrued salary of $512,500; $250,000 convertible note issued to Executive at 4% interest, conversion (effective 2023-01-23).","evidence_excerpt":"On January 23, 2023, the Company entered into a “Settlement Agreement” with its Chief Executive Officer, John W. Huemoeller II (the \"Executive\") regarding $512,500 of accrued and unpaid salary owed to the Executive through December 31, 2022 (the \"Amount Due\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1514946/000109690623000219/0001096906-23-000219-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"John W. Huemoeller II"},{"label":"Value","value":"Accrued salary of $512,500; $250,000 convertible note issued to Executive at 4% interest, conversion"},{"label":"Effective","value":"2023-01-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}